Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 1, 2004, Pages 27-32

  Westendorp, Bart ^a   Schoemaker, Regien G ^a,b   Buikema, Hendrik ^a   de Zeeuw, Dick ^a   van Veldhuisen, Dirk J ^b   van Gilst, Wiek H ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibition; Dietary sodium restriction; Hypertrophy; Myocardial infarction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HEART PERFUSION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; KIDNEY PARENCHYMA; MALE; NONHUMAN; ORGAN WEIGHT; RAT; SODIUM RESTRICTION; TISSUE LEVEL; TISSUE SPECIFICITY;

EID: 1842687001     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.004     Document Type: Article

References (34)

1. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
2. Flather MD, Yusuf S, Kober I, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
3. Brogden RN, Todd PA, Sorkin EM. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988;36:540-600.
4. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of raimpril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997;18:41-51.
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
6. Konstam MA, Rousseau MF, Kronenberg MW et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431-8.
7. Navis G, de Jong P, Donker AJ, van der Hem GK, de Zeeuw D. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987;9:743-8.
8. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect ofACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
9. Gansevoort RT, Wapstra FH, Weening JJ, de Jong PE, de Zeeuw D. Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis. Nephron 1992;60:246-7.
10. Fernandez D, Bolli P, Snedden W, Vasdev S, Fernandez PG. Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme. J Hypertens 1988;6(suppl):S145-S147.
11. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.
12. Pinto YM, de Smet BG, van Gilst WH et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8.
13. Pfeffer MA, Pfeffer JM, Fishbein MC et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
14. Nelissen-Vrancken HJ, Kuizinga MC, Daemen MJ, Smits JF. Early captopril treatment inhibits DNA synthesis in endothelial cells and normalization of maximal coronary flow in infarcted rat hearts. Cardiovasc Res 1998;40:156-64.
15. Schoemaker RG, Debets JJ, Struyker-Boudier HA, Struts JF. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol 1991;23:187-97.
16. Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 1971;250:261-5.
17. Seeland U, Kouchi I, Zolk O et al. Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats. Eur J Heart Fail 2003;5:241-6.
18. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 1996;28:851-8.
19. Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994;28:1423-32.
20. van Wijngaarden J, Pinto YM, van Gilst WH, de Graeff PA, de Langen CD, Wesseling H. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovasc Res 1991; 25:936-42.
21. Wollert KC, Studer R, von Bulow B, Drexler H. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-67.
22. Hodsman GP, Sumithran E, Harrison RW, Johnston CI. Cardiac hypertrophy and salt status in chronic myocardial infarction in the rat: effects of enalapril versus salt restriction. J Cardiovasc Pharmacol 1988;12:467-72.
23. Kreutz R, Fernandez-Alfonso MS, Liu Y, Ganten D, Paul M. Induction of cardiac angiotensin I-converting enzyme with dietary NaCl-loading in genetically hypertensive and normotensive rats. J Mol Med 1995;73:243-8.
24. Schmid C, Castrop H, Reitbauer J, Della BR, Kurtz A. Dietary salt intake modulates angiotensin II type 1 receptor gene expression. Hypertension 1997;29:923-9.
25. Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Bohm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo.Hypertension 1998;31:1272-7.
26. Ruan X, Wagner C, Chatziantoniou C, Kurtz A, Arendshorst WJ. Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet. J Clin Invest 1997;99:1072-81.
27. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98:2765-73.
28. Regitz-Zagrosek V, Fielitz J, Fleck E. Myocardial angiotensin receptors in human hearts. Basic Res Cardiol 1998;93(suppl 2):37-42.
29. Yoshida K, Kohzuki M, Casley DJ, Johnston CI. Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction. J Cardiovasc Pharmacol 1998;32:357-65.
30. Teisman AC, Pinto YM, Buikema H et al. Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats. J Hypertens 1998;16(12 Pt 1):1759-65.
31. Kalkman EA, Saxena PR, Schoemaker RG. Sensitivity to ischemia of chronically infarcted rat hearts; effects of long-term captopril treatment. Eur J Pharmacol 1996;298:121-8.
32. Mill JG, Gomes AP, Carrara AB, Gomes MG, Vassallo DV. Influence of chronic captopril therapy on the mechanical performance of the infarcted rat heart. Pharmacol Res 1994; 29:77-88.
33. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992; 19:1136-44.
34. Pfeffer MA, Braunwald E. Ventricular enlargement following infarction is a modifiable process. Am J Cardiol 1991; 68:127D-131D.